(NEO) NeoGenomics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US64049M2098
Stock: Cancer Testing, Genetic Analysis, Pathology, Diagnostics
Total Rating 19
Risk 48
Buy Signal -0.79
| Risk 5d forecast | |
|---|---|
| Volatility | 67.2% |
| Relative Tail Risk | -19.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | -35.90 |
| Character TTM | |
|---|---|
| Beta | 0.989 |
| Beta Downside | 1.240 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.65% |
| CAGR/Max DD | -0.29 |
EPS (Earnings per Share)
Revenue
Description: NEO NeoGenomics March 05, 2026
NeoGenomics, Inc. operates cancer-focused testing laboratories in the US and UK. The company provides a range of oncology testing services to various healthcare entities and pharmaceutical companies. This business model relies on specialized diagnostic services.
Their services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, and digital imaging. They also offer molecular testing and morphologic analysis. These services are critical for cancer diagnosis and treatment planning.
NeoGenomics supports pharmaceutical clients oncology programs from discovery to commercialization. The company, founded in 2001 and headquartered in Fort Myers, Florida, is part of the Health Care Services sector. To understand NeoGenomics market position and financial health, further research on ValueRay is recommended.
Headlines to watch out for
- Oncology testing demand drives laboratory service revenue
- Pharmaceutical research contracts boost specialized testing
- Reimbursement rates for cancer diagnostics impact profitability
- Regulatory changes in laboratory testing create compliance costs
- Competition from large diagnostic companies pressures market share
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -108.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 0.48 > 1.0 |
| NWC/Revenue: 39.59% < 20% (prev 44.63%; Δ -5.03% < -1%) |
| CFO/TA 0.00 > 3% & CFO 5.23m > Net Income -108.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.7m) vs 12m ago 1.57% < -2% |
| Gross Margin: 42.16% > 18% (prev 0.44%; Δ 4.17k% > 0.5%) |
| Asset Turnover: 48.52% > 50% (prev 40.33%; Δ 8.20% > 0%) |
| Interest Coverage Ratio: -28.36 > 6 (EBITDA TTM -38.6m / Interest Expense TTM 3.75m) |
Altman Z'' -1.00
| A: 0.21 (Total Current Assets 376.3m - Total Current Liabilities 88.3m) / Total Assets 1.36b |
| B: -0.32 (Retained Earnings -433.8m / Total Assets 1.36b) |
| C: -0.07 (EBIT TTM -106.5m / Avg Total Assets 1.50b) |
| D: -0.83 (Book Value of Equity -433.7m / Total Liabilities 523.3m) |
| Altman-Z'' Score: -1.00 = CCC |
Beneish M -2.95
| DSRI: 0.96 (Receivables 159.2m/150.5m, Revenue 727.3m/660.6m) |
| GMI: 1.04 (GM 42.16% / 43.92%) |
| AQI: 1.14 (AQ_t 0.60 / AQ_t-1 0.53) |
| SGI: 1.10 (Revenue 727.3m / 660.6m) |
| TATA: -0.08 (NI -108.0m - CFO 5.23m) / TA 1.36b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of NEO shares?
As of March 23, 2026, the stock is trading at USD 7.96 with a total of 3,127,988 shares traded.
Over the past week, the price has changed by -3.40%, over one month by -20.16%, over three months by -35.91% and over the past year by -21.65%.
Over the past week, the price has changed by -3.40%, over one month by -20.16%, over three months by -35.91% and over the past year by -21.65%.
Is NEO a buy, sell or hold?
NeoGenomics has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy NEO.
- StrongBuy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NEO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.8 | 86.1% |
| Analysts Target Price | 14.8 | 86.1% |
NEO Fundamental Data Overview March 20, 2026
P/E Forward = 222.2222
P/S = 1.4296
P/B = 1.2833
P/EG = 2.0871
Revenue TTM = 727.3m USD
EBIT TTM = -106.5m USD
EBITDA TTM = -38.6m USD
Long Term Debt = 341.9m USD (from longTermDebt, last quarter)
Short Term Debt = 4.78m USD (from shortTermDebt, last quarter)
Debt = 472.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 312.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.35b USD (1.04b + Debt 472.3m - CCE 159.6m)
Interest Coverage Ratio = -28.36 (Ebit TTM -106.5m / Interest Expense TTM 3.75m)
EV/FCF = -62.10x (Enterprise Value 1.35b / FCF TTM -21.8m)
FCF Yield = -1.61% (FCF TTM -21.8m / Enterprise Value 1.35b)
FCF Margin = -2.99% (FCF TTM -21.8m / Revenue TTM 727.3m)
Net Margin = -14.85% (Net Income TTM -108.0m / Revenue TTM 727.3m)
Gross Margin = 42.16% ((Revenue TTM 727.3m - Cost of Revenue TTM 420.7m) / Revenue TTM)
Gross Margin QoQ = 39.81% (prev 42.84%)
Tobins Q-Ratio = 0.99 (Enterprise Value 1.35b / Total Assets 1.36b)
Interest Expense / Debt = 0.13% (Interest Expense 599k / Debt 472.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.1m (EBIT -106.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.26 (Total Current Assets 376.3m / Total Current Liabilities 88.3m)
Debt / Equity = 0.56 (Debt 472.3m / totalStockholderEquity, last quarter 836.6m)
Debt / EBITDA = -8.09 (negative EBITDA) (Net Debt 312.7m / EBITDA -38.6m)
Debt / FCF = -14.36 (negative FCF - burning cash) (Net Debt 312.7m / FCF TTM -21.8m)
Total Stockholder Equity = 854.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.21% (Net Income -108.0m / Total Assets 1.36b)
RoE = -12.64% (Net Income TTM -108.0m / Total Stockholder Equity 854.3m)
RoCE = -8.90% (EBIT -106.5m / Capital Employed (Equity 854.3m + L.T.Debt 341.9m))
RoIC = -6.75% (negative operating profit) (NOPAT -84.1m / Invested Capital 1.25b)
WACC = 6.54% (E(1.04b)/V(1.51b) * Re(9.46%) + D(472.3m)/V(1.51b) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF] Fair Price = unknown (Cash Flow -21.8m)
EPS Correlation: 59.49 | EPS CAGR: 144.0% | SUE: 0.21 | # QB: 0
Revenue Correlation: 98.39 | Revenue CAGR: 13.79% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.04 | Chg7d=+0.000 | Chg30d=-0.005 | Revisions Net=-4 | Analysts=10
EPS current Year (2026-12-31): EPS=0.16 | Chg7d=+0.000 | Chg30d=-0.018 | Revisions Net=-2 | Growth EPS=+31.8% | Growth Revenue=+9.5%
EPS next Year (2027-12-31): EPS=0.32 | Chg7d=+0.000 | Chg30d=-0.058 | Revisions Net=-3 | Growth EPS=+101.7% | Growth Revenue=+9.9%
[Analyst] Revisions Ratio: -0.67 (1 Up / 5 Down within 30d for Next Quarter)
P/S = 1.4296
P/B = 1.2833
P/EG = 2.0871
Revenue TTM = 727.3m USD
EBIT TTM = -106.5m USD
EBITDA TTM = -38.6m USD
Long Term Debt = 341.9m USD (from longTermDebt, last quarter)
Short Term Debt = 4.78m USD (from shortTermDebt, last quarter)
Debt = 472.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 312.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.35b USD (1.04b + Debt 472.3m - CCE 159.6m)
Interest Coverage Ratio = -28.36 (Ebit TTM -106.5m / Interest Expense TTM 3.75m)
EV/FCF = -62.10x (Enterprise Value 1.35b / FCF TTM -21.8m)
FCF Yield = -1.61% (FCF TTM -21.8m / Enterprise Value 1.35b)
FCF Margin = -2.99% (FCF TTM -21.8m / Revenue TTM 727.3m)
Net Margin = -14.85% (Net Income TTM -108.0m / Revenue TTM 727.3m)
Gross Margin = 42.16% ((Revenue TTM 727.3m - Cost of Revenue TTM 420.7m) / Revenue TTM)
Gross Margin QoQ = 39.81% (prev 42.84%)
Tobins Q-Ratio = 0.99 (Enterprise Value 1.35b / Total Assets 1.36b)
Interest Expense / Debt = 0.13% (Interest Expense 599k / Debt 472.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.1m (EBIT -106.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.26 (Total Current Assets 376.3m / Total Current Liabilities 88.3m)
Debt / Equity = 0.56 (Debt 472.3m / totalStockholderEquity, last quarter 836.6m)
Debt / EBITDA = -8.09 (negative EBITDA) (Net Debt 312.7m / EBITDA -38.6m)
Debt / FCF = -14.36 (negative FCF - burning cash) (Net Debt 312.7m / FCF TTM -21.8m)
Total Stockholder Equity = 854.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.21% (Net Income -108.0m / Total Assets 1.36b)
RoE = -12.64% (Net Income TTM -108.0m / Total Stockholder Equity 854.3m)
RoCE = -8.90% (EBIT -106.5m / Capital Employed (Equity 854.3m + L.T.Debt 341.9m))
RoIC = -6.75% (negative operating profit) (NOPAT -84.1m / Invested Capital 1.25b)
WACC = 6.54% (E(1.04b)/V(1.51b) * Re(9.46%) + D(472.3m)/V(1.51b) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF] Fair Price = unknown (Cash Flow -21.8m)
EPS Correlation: 59.49 | EPS CAGR: 144.0% | SUE: 0.21 | # QB: 0
Revenue Correlation: 98.39 | Revenue CAGR: 13.79% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.04 | Chg7d=+0.000 | Chg30d=-0.005 | Revisions Net=-4 | Analysts=10
EPS current Year (2026-12-31): EPS=0.16 | Chg7d=+0.000 | Chg30d=-0.018 | Revisions Net=-2 | Growth EPS=+31.8% | Growth Revenue=+9.5%
EPS next Year (2027-12-31): EPS=0.32 | Chg7d=+0.000 | Chg30d=-0.058 | Revisions Net=-3 | Growth EPS=+101.7% | Growth Revenue=+9.9%
[Analyst] Revisions Ratio: -0.67 (1 Up / 5 Down within 30d for Next Quarter)